Join Quotient Sciences for a complimentary Lunch & Learn Seminar on Tuesday, November 5th from 11:00am to 1:00pm during AAPS entitled:
Analysis from the Tufts Center for the Study of Drug Development to Assess the Financial Benefits from Translational Pharmaceutics®: A Platform for Accelerating Product Development
The drug development process has been demonstrated to be highly costly, lengthy, and risky with significant rates of molecule attrition. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier on average. To inform drug developers of the potential financial impacts of alternative drug development processes and outsourcing models, the Tufts CSDD conducted a study comparing traditional drug development programs to Quotient Sciences’ signature drug product manufacturing and formulation platform, referred to as Translational Pharmaceutics, which has been widely used by pharmaceutical and biotech companies to accelerate product development. Key applications of Translational Pharmaceutics include the transition of molecules from First in Human (FIH) to proof of concept (POC), and in the development and optimization of clinical formulations. This presentation will provide a summary of the key findings of the Tufts CSDD research, with respect to the impact on development cycle times and their derivative effects on development economics and financial gains.
When: Tuesday, November 5th
Time: 11:00am to 1:00pm
Speaker: Peter Scholes, CSO at Quotient Sciences
Location: Ruth Chris' Steakhouse - 600 E Market St, San Antonio, TX 78205 (Inside the Grand Hyatt, right next to the convention center)
Space is limited, so reserve your spot today!